InnoCan Pharma (INNO) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 surged 29.7% sequentially to $6.47M, reflecting strong operational momentum.

• Gross margin remained robust at 91.1%, supporting sustained profitability.

• Strategic focus shifted to scaling core operations, deferring the planned US IPO.

• Proprietary LPT-CBD platform and diversified business model highlighted as key growth drivers.

Financial highlights

• Q1 2026 revenue was $6.465M, up 29.7% from Q4 2025 but down 17.07% year-over-year.

• Gross profit reached $5.89M, up 32.97% sequentially but down 17.2% year-over-year.

• Operating loss was $0.786M, a 14.67% improvement from Q4 2025 but a 261.1% increase year-over-year.

• Gross margin held steady at 91.1%.

Outlook and guidance

• Management remains optimistic about long-term growth, citing resilience amid global market volatility.

• Focus remains on operational execution and market expansion.

• Regulatory progress with FDA 505(b)(2) pathway and animal health catalysts expected to drive future growth.